Bell TJ, Hoerger TJ, Tran MH, Candrilli SD, Wojczynski MK. Distribution of low-density lipoprotein cholesterol levels and treatment patterns in treatment-eligible United States adults based on the ncep atp iii guidelines. Poster presented at the 3rd Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; September 2001.
Buchner DA, Graboys TB, Johnson K, Mordin MM, Goodman L, Partsch DS, Goss TF. Development and validation of the ITG Health-Related Quality-of- Life Short-Form measure for use in patients with coronary artery disease. Integrated Therapeutics Group. Clin Cardiol. 2001 Aug;24(8):556-63.
Lurdes Comas Mongay M, Castellote Alonso E, Feixas Roma J, Pladevall-Vila M. TheCholesterol2000document: is itusefulforrenalpatients? Rev Esp Cardiol. 2001 Jun;54(6):807-8.
Anthony MS. Soy and cardiovascular disease. Presented at the 11th World Congress of Food Science and Technology; April 22, 2001. Seoul, South Korea.
Guyer H, Pladevall-Vila M, Yanez A, Falces C, Sadurni J, Ribes A, Pare C. The relationship between syndrome x and left ventricular hypertrophy: the impact of different methods of adjusting left ventricular mass. Poster presented at the AHA Conference on Cardiovascular Epidemiology; 2001.
Talmud PJ, Berglund L, Hawe E, Waterworth DM, Isasi CR, Deckelbaum RE, Starc T, Ginsberg HN, Humphries SE, Shea S. Age-related effects of genetic variation on lipid levels: the Columbia University BioMarkers Study. Pediatrics. 2001;108(3):E50.
Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE. Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost. 2001;85(1):67-74.
Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 2001 Jan 1;153(1):79-89.
Varas-Lorenzo C, Perez-Gutthann S, Castellsague J, Gutierrez LP. Effects of transdermal hormone replacement therapy on cardiovascular outcomes: epidemiological evidence. In: Genazzani AR, editors. Hormone replacement therapy and cardiovascular disease. New York: United States. The Partenon Publishing Group Limited; 2001.
Anthony MS. Soy protein and heart disease. In: Descheemaeker K, Debruyne I, editors. Soy and health 2000 clinical evidence-dietetic applications. Belgium. Garant, Leuven/Apeldoorn; 2001. p.11-6.
Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22(24):2243-52.
Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001;358(9276):115-9.
Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. J Med Econ. 2001 Jan 1;4:199-205.
Zierler S, Theodore M, Cohen A, Rothman KJ. Chemical quality of maternal drinking water and congenital heart disease. Int J Epidemiol. 1988 Sep;17(3):589-94.